PAD: PROMISE II Trial: Deep-Vein Arterialization Shows Promise for No-Option CLTI Patients.

https://is1-ssl.mzstatic.com/image/thumb/Podcasts122/v4/82/43/b7/8243b73b-2d11-1311-21be-68683a295068/mza_12804423687283069731.jpg/600x600bb.jpg

'Why we do What we do in Cardiology'

Bishnu Subedi

35 episodes

5 days ago

I am Dr. Bishnu Subedi. I am a cardiologist in the United States. In the era of evidence-based medicine, our practice is usually guided by a scientific study, expert society statements, or clinical guidelines. In this podcast series, I intend to highlight some of these practice-changing articles in the field of cardiology from past and present.

Medicine

Health & Fitness

RSS

All content for 'Why we do What we do in Cardiology' is the property of Bishnu Subedi and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Medicine

Health & Fitness

https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded_nologo/5443800/5443800-1710051687903-3d02caa2ebc39.jpg

PAD: PROMISE II Trial: Deep-Vein Arterialization Shows Promise for No-Option CLTI Patients.

'Why we do What we do in Cardiology'

2 minutes 43 seconds

1 year ago

PAD: PROMISE II Trial: Deep-Vein Arterialization Shows Promise for No-Option CLTI Patients.

Key Points from PROMISE 2 Trial:

• Problem: 20% of CLTI patients have no revascularization options, leading to amputations.

• Solution: Transcatheter arterialization of deep veins creates an artery-to-vein connection, delivering oxygenated blood to the ischemic foot and potentially preventing amputation.

• Study: Analyzed 105 patients with no other treatment options who underwent the procedure with LimFlow Device.

• Results:

o Amputation-free survival at 6 months: 66.1%, exceeding the 54% performance goal.

o Limb salvage: 76.0%.

o Wound healing: 25% completely healed, 51% in progress.

o Safety: No unanticipated device-related adverse events.

• Conclusion: Deep-vein arterialization is a safe and effective option for no-option CLTI patients, offering limb salvage, wound healing, and improved survival.

Article Link: DOI: 10.1056/NEJMoa2212754